

## Autoantibody Prevalence in Chronic Hepatitis C Patients in Latvia

*Elvira Hagina<sup>1</sup>, Frida Arsh<sup>3</sup>, Velga Kuse<sup>3</sup>, Jelena Eglite<sup>1</sup>,  
Artur Sochnevs<sup>1</sup>, Ludmila Viksna<sup>2,3</sup>*

<sup>1</sup> Rīga Stradiņš University, Laboratory of Clinical Immunology and Immunogenetics, Latvia

<sup>2</sup> Rīga Stradiņš University, Department of Infectology and Dermatology, Latvia

<sup>3</sup> Riga Eastern Clinical University Hospital, Infectology Center of Latvia

**Introduction.** Hepatitis C is one of the major health problems. There are 150 million chronic carriers throughout the world. Chronic hepatitis C (CHC) is known to be the disease with pronounced autoimmune component that is caused by various subtypes of hepatitis C virus (HCV). Various geographical regions are characterized by certain autoantibody prevalence in sera of CHC patients. HCV types 2, 3, 4 infections have better prognosis than HCV type 1 related CHC. This study presents the results of autoantibodies detection in CHC patients in Latvia.

**The aim.** The aim of this research was to study autoantibody prevalence in CHC patients infected with various types of HCV.

**Materials and methods.** Sera of 33 patients with epidemiological, clinical, serological, biochemical, morphological evidence of HCV infection and duration of hepatitis at least 6 months were examined on presence of autoantibodies before the treatment. Five types of autoantibodies were tested in indirect immunofluorescence on rat tissues: ANA – antinuclear antibody, SMS – smooth muscle antibody, anti-LKM – liver-kidney microsomal antibody, anti-GPC – antibody to gastric parietal cells, AMA – antimitochondrial antibody (The Binding Site Ltd., England). The types of HCV were detected using Murex HCV Serotyping 1–6 Assay.

**Results.** 39% of patients of CHC had no autoantibodies in sera before treatment, 3% had anti-GPC, 3% – anti-LKM, 9% – ANA, 9% – SMA + anti GPC, 18% – SMA and 18% – SMA + ANA. Prevalence of SMA and ANA in CHC patients was higher than anti-GPC and anti-LKM. Among SMA positive patients, 20% had titer 1 : 40, 40% had titer 1 : 80 and 40% had titer 1 : 160. Anti-LKM positive patient had titer 1 : 640. Frequency of autoantibody presence in sera was higher in patients with HCV type 1 than in HCV types 2–4 infected ones.

**Conclusions.** According to the results of our study, there was a high prevalence of SMA, average – of ANA and anti-GPC and low – of anti-LKM in CHC patients. Autoantibodies were more frequently found in sera of CHC patients infected by HCV type 1 versus those who were infected by HCV types 2–4. The patients with HCV type 1 could have higher risk of autoimmune component than the patients with HCV types 2, 3, 4.